Oss, The Netherlands, Erlangen, Germany September 18, 2019 —http://www.citryll.com/ announced today that it has established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University of Erlangen-Nürnberg to investigate the mechanism of action (MoA) of its lead CIT-013 (tACPA) antibody programme.CIT-013 interferes with the formation, function and clearance of neutrophil… Read More


Citryll’s CIT-013 could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis and organ damage due to sepsis Lonza’sin silicopreclinical services used to assess manufacturability and immunogenicity Lonza to supply final drug product in finished format for Citryll’s clinical studies Oss, The Netherlands and Basel, Switzerland, 9 September 2019– The Netherlands-based… Read More